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Angiotensin 1-7 (Ang 1-7) enhances insulin signaling and glucose transport activity in the skeletal muscle. The aim of our study was
to evaluate the effect of AVE0991, a nonpeptide Mas receptor agonist, on the metabolic parameters, expression of RAS components
and markers of oxidative stress, and insulin signaling in the skeletal morbidly obese rats. 33-week-old male obese Zucker rats were
treated with vehicle and AVE0991 (0.5mg/kg BW/day) via osmotic minipumps for two weeks. Gene expressions were determined
by qPCR and/or Western blot analysis in musculus quadriceps. The enzymatic activities were detected flourometrically
(aminopeptidase A) or by colorimetric assay kit (protein tyrosine phosphatase 1B). Administration of AVE0991 enhanced
insulin signaling cascade in the skeletal muscle, reflected by improved whole-body glucose tolerance. It has been shown that
reactive oxygen species (ROS) have insulin-mimetic action in muscle. The expression of renin receptor, transcription factor
PLZF, and prooxidant genes was upregulated by AVE0991 accompanied by elevated expression of genes coding enzymes with
antioxidant action. Our results show that AVE0991 administration activates genes involved in both ROS generation and
clearance establishing a new prooxidant/antioxidant balance on a higher level, which might contribute to the improved insulin
signaling pathway and glucose tolerance of obese Zucker rats.
1. Introduction
The renin-angiotensin system (RAS) is well known as an
essential regulator of systemic blood pressure as well as fluid
and electrolyte homeostasis. The classic understanding of the
RAS has changed by the evidence of local tissue-specific for-
mation of several RAS components, including skeletal muscle
in vitro and in vivo. Local RAS in the skeletal muscle
responds to physiological stimuli; it is capable of de novo
angiotensin II (Ang II) production and can function inde-
pendently of systemic RAS. Ang II has long been considered
to be the single critical product of the RAS, which acts via
two types of receptors: AT1 and AT2. Most of Ang II
effects are mediated by the AT1 receptor, including vaso-
constriction, hypertrophy, and cellular growth. Several lines
of evidence have demonstrated the existence of two func-
tionally opposing pathways of the RAS. The alternative
pathway of the RAS involves the cleavage of Ang I or Ang
II by angiotensin-converting enzyme 2 (ACE2) to Ang 1-7.
Ang 1-7 acts via a Mas receptor and has antagonistic effects
to the classical RAS pathway; it is able to improve insulin sig-
naling and glucose transport activity in the skeletal muscle by
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enhanced insulin receptor substrate 1 (IRS1) and Akt kinase
phosphorylation [1, 2]. Ang 1-7 has beneficial effect on skel-
etal muscle perfusion as well, since it evokes dilatation of pre-
capillary arterioles. The major limitation of exogenous
administration of Ang 1-7 is that it is a peptide with very
short biological half-life and low oral bioavailability.
AVE0991, a nonpeptide Mas receptor agonist, has been
reported to mimic the effects of Ang 1-7. The main advan-
tages of this compound are its stability, oral activity, and
resistance against proteolytic enzymes [3, 4]. The effect of
AVE0991 on the physiology of skeletal muscle has not been
examined yet.
The aim of our study was to evaluate the effect of
AVE0991 application on the (i) metabolic parameters, (ii)
expression of the RAS components and (iii) markers of oxi-
dative stress, and (iv) insulin signaling in the skeletal muscle
of obese Zucker rats.
2. Materials and Methods
2.1. Animals. Male Zucker fatty rats (fa/fa) (n = 11) were
purchased from Harlan (Udine, Italy). The animals were
housed in a 12-hour light/dark cycle with access to water
and standard diet ad libitum. Animals were separated to
two groups. The control group was treated with vehicle
(30% solution of cyclodextrin), and the experimental group
received AVE0991 (Sanofi-Aventis, Frankfurt, Germany)
(0.5mg/kg BW/day in 30% solution of cyclodextrin) via
osmotic minipumps (ALZET, CA, USA) for two weeks. The
intraperitoneal glucose tolerance test (IPGTT) was performed
to assess glucose clearance. On the 12th day, overnight-fasted
animals were administered an i.p. injection of dextrose solu-
tion at a dose of 2 g/kg body weight. Glycaemia was measured
in the tail vein blood immediately and in 30-minute intervals
for 2 hours after glucose administration using a glucometer
(Accu-Chek Active, Roche Diagnostics, Switzerland). After
2 days of recovery, overnight-fasted animals were sacrificed
by decapitation at the age of 8 months. Experimental proce-
dures involving animals were approved by the Jagiellonian
University Ethical Committee on Animal Experiments.
2.2. Measurement of Selected Metabolic Parameters. Circulat-
ing insulin level was measured in plasma isolated from trunk
blood samples obtained after decapitation using commer-
cial radioimmunoassay kit (Millipore, Bedford, MA, USA)
following the manufacturer’s protocol. Lipid parameters
were determined in the Laboratory Diagnostics Unit of the
University Hospital in Krakow using commercially available
kits (Roche Molecular Diagnostics, Pleasanton, CA, USA).
Fasting glycaemia was analysed at SYNLAB (Bratislava,
Slovakia) using multianalyzer COBAS INTEGRA 800 (Roche
Diagnostics Ltd., Rotkreuz, Switzerland). Quantitative insu-
lin sensitivity check index (QUICKI) was calculated as fol-
lows: inverse of the sum of the logarithms of the fasting
insulin (μU/ml) and fasting glucose (mg/dl).
2.3. RNA Isolation and Real-Time PCR. Prior to sampling for
RNA, dissected samples of quadriceps muscle were snap-
frozen and mashed under liquid nitrogen to powder. Samples
were stored at -80°C until analyses. Total RNA was isolated
frommusculus quadriceps using RNeasy Plus Universal Mini
Kit (Qiagen, Valencia, CA, USA), and reverse transcription
was performed using Maxima First Strand cDNA Synthesis
Kit (Thermo Fisher, Waltham, MA, USA) according to the
manufacturer’s protocol. Real-time PCRs were carried out
applying Maxima SYBR Green qPCR Master Mix (Thermo
Fisher, Waltham, MA, USA) and run on an ABI 7900HT
thermal cycler (Applied Biosystems, Life Technologies,
Carlsbad, CA, USA) using rat-specific primer pairs shown
in Table 1. Data were normalized to the expression of house-
keeping gene ribosomal protein S29 (Rps29) which was not
altered by the treatment.
2.4. Western Blotting. Samples of musculus quadriceps were
homogenized using a glass Teflon homogenizer in an ice-
cold lysis buffer (10mM Tris-HCl, pH 8.0, 150mM NaCl,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS,
0.5mM dithiothreitol, 1mM phenylmethylsulphonyl fluo-
ride, 5mg/ml leupeptin, and 5mg/ml aprotinin). Homoge-
nates were placed on ice for 2 h with occasional mixing
and centrifuged at 16000 g/20min/4°C. The supernatant
was used for Western blot analysis. Protein concentration
was determined by Bicinchoninic Acid Protein Assay Kit
(Sigma-Aldrich, St. Louis, MO, USA) according to the man-
ufacturer’s instructions. Proteins were separated by SDS-
PAGE technique on 10% polyacrylamide gels and electro-
transferred in semidry conditions to a low-fluorescence
PVDF membrane (Immobilon-FL, Millipore, Bedford, MA,
USA). The equal loading and transfer was confirmed by
Ponceau staining (SERVA, Heidelberg, Germany). Mem-
branes were blocked in 5% bovine serum albumin (BSA) in
Tris-Buffered Saline for 1 h at room temperature and incu-
bated overnight at 4°C with primary antibody against insulin
receptor β (#3025, Abcam, Cambridge, MA, USA) diluted
1 : 1000, phospho-IGF-I receptor β (Tyr1135/1136)/insulin
receptor β (Tyr1150/1151) (#3024, Abcam, Cambridge,
MA, USA) diluted 1 : 1000, IRS1 (#2382, Abcam, Cambridge,
MA, USA) diluted 1 : 1000, phospho-IRS1 (Tyr896) (LS-
C381052, LifeSpan BioSciences, Inc., Seattle, WA, USA)
diluted 1 : 500, phospho-IRS1 (Ser307) (#2381, Abcam, Cam-
bridge, MA, USA) diluted 1 : 1000, phospho-IRS1 (Ser612)
(#2386, Abcam, Cambridge, MA, USA) diluted 1 : 1000, Akt
(#9272, Abcam, Cambridge, MA, USA) diluted 1 : 1000,
phospho-Akt (Thr308) (#9275, Abcam, Cambridge, MA,
USA) diluted 1 : 1000, PTP1B (LS-C385670, LifeSpan BioSci-
ences, Inc., Seattle, WA, USA) diluted 1 : 1500, and phospho-
PTP1B (Ser50) (LS-C381317, LifeSpan BioSciences, Inc.,
Seattle, WA, USA) diluted 1 : 1500 in 5% BSA in Tris-
Buffered Saline. After washing in TBS with Igepal, the mem-
branes were incubated with fluorescently labelled secondary
anti-rabbit (#5151) or anti-mouse (#5257) antibodies (Cell
Signaling Technology, Danvers, MA, USA) diluted 1 : 15000
for 1 h at room temperature. Infrared fluorescence was
detected using the Odyssey Infrared Imaging System (LI-
COR Biosciences, Lincoln, NE, USA), and Odyssey IR Imag-
ing System software version 2.0 was used for analysis. As the
protein expressions of the tested endogenous loading con-
trols (GAPDH, β-actin, and α-tubulin) displayed significant
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Table 1: Primer sequences used for qPCR.
Ace
Fw 5′-ATG GTA CAG AAG AAG GGC TGG AA-3′
Rv 5′-TTG TAG AAG TCC CAC GCA GA-3′
Ace2
Fw 5′-TCA GAG CTG GGA TGC AGA AA-3′
Rv 5′-GGC TCA GTC AGC ATG GAG TTT-3′
Agt
Fw 5′-CAT GAG TTC TGG GTG GAC AA-3′
Rv 5′-AAG TTG TTC TGG GCG TCA CT-3′
Apa (Enpep)
Fw 5′-GGC TCC CTT GTG GGT TTT TAC-3′
Rv 5′-TCT TGT TGG GTT CAT CGA AAC A-3′
AT1 (Agtr1a)
Fw 5′-TCT CAG CAT CGA TCG CTA CCT-3′
Rv 5′-AGG CGA GAC TTC ATT GGG TG-3′
AT2
Fw 5′-ACC TTT TGA ACA TGG TGC TTT G-3′
Rv 5′-GTT TCT CTG GGT CTG TTT GCT C-3′
Furin
Fw 5′-GGG TTT CCC AGC AGT CTT CA-3′
Rv 5′-GCC AGA TCC CCA GGT GTG-3′
Mas1 (MasR)
Fw 5′-TGA CCA TTG AAC AGA TTG CCA-3′
Rv 5′-TGT AGT TTG TGA CGG CTG GTG-3′
Nep (Mme)
Fw 5′-GCA GAA ATC AGA TCG TCT TCC CCG-3′
Rv 5′-CTG AGT CCA CCA GTC AAC GAG GT-3′
Nox2
Fw 5′-TGA TCA TCA CAT CCT CCA CCA A-3′
Rv 5′-GAT GGC AAG GCC GAT GAA-3′
Nox4
Fw 5′-CTGCATCTGTCCTGAACCTCAA-3′
Rv 5′-TCTCCTGCTAGGGACCTTCTGT-3′
Nrf2
Fw 5′-GTT GAG AGC TCA GTC TTC AC-3′
Rv 5′-CAG AGA GCT ATC GAG TGA CT-3′
p22phox
Fw 5′-TGGCCTGATCCTCATCACAG-3′
Rv 5′-AGGCACGGACAGCAGTAAGT-3′
Plzf (Zbtb16)
Fw 5′-GCGAAGAAGAAGAGGACCGTAAG-3′
Rv 5′-CCGGAATGCTTCGAGATGAA-3′
Renín
Fw 5′-CCA CCT TCA TCC GCA AGT TC-3′
Rv 5′-TGC GAT TGT TAT GCC GGT C-3′
Rer (Atp6ap2)
Fw 5′-TGG CCT ATA CCA GGA GAT CG-3′
Rv 5′-AAT AGG TTG CCC ACA GCA AG-3′
Rps29
Fw 5′-GCTGAACATGTGCCGACACT-3′
Rv 5′-GGTCGCTTAGTCCAACTTAATGAA-3′
Sod1
Fw 5′-CAC TCT AAG AAA CAT GGC G-3′
Rv 5′-CTG AGA GTG AGA TCA CAC G-3′
Sod2 Fw 5′-TTC AGC CTG CAC TGA AG-3′
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variations upon obesity [5] and AVE0991 treatment; the sig-
nal intensities of the proteins of interest were normalized to
the sample’s total protein content stained with Coomassie
Brilliant Blue [6]. Briefly, after membrane scanning and sub-
sequent washing, blots were stained for 1min (0.04% Coo-
massie Brilliant Blue (w/v), 40% methanol (v/v), and 5%
acetic acid (v/v)), destained for 2min (40% methanol (v/v)
and 5% acetic acid (v/v)), washed in water, and dried. Signal
corresponding to total proteins on the blot was analysed by
software ImageJ 1.42q (NIH, USA).
2.5. Measurement of Enzyme Activities. Skeletal muscle was
homogenized using a glass Teflon homogenizer in lysis buffer
(250mM saccharose, 10mM Tris, and pH 7.4). The homog-
enate was centrifuged at 1000 x g/10min/4°C. The superna-
tant was collected and centrifuged at 16000 x g/15min/4°C
to separate the membrane fraction. Protein concentration
was measured by the Bicinchoninic Acid Protein Assay
(Sigma-Aldrich, St. Louis, MO, USA). Activity of aminopep-
tidase A (APA) was determined in the membrane fraction.
The samples were mixed with substrate solution containing
10mg/100ml bovine serum albumin, 10mg/100ml dithio-
threitol, 50mM CaCl2 in 50mM Tris pH 7.4, and 100mM
H-Glu-β-naphthylamide (Bachem, Bubendorf, Switzerland),
which served as a substrate for APA. The 96-well was placed
in a Synergy™ H4 Hybrid Reader (BioTek, Winooski, VT,
USA) fluorimeter and preheated to 37°C. The enzyme kinet-
ics was measured during 60 minutes in 5-minute intervals as
the amount of β-naphthylamide was released from the sub-
strate due to the enzyme activity of APA at wavelengths
340nm (excitation) and 410nm (emission). Enzyme activity
is expressed in micromoles per liter of H-Glu-β-naphthyla-
mide hydrolysed per minute per milligram of protein. Activ-
ity of PTP1B was determined in the cytosolic fraction using
the commercially available PTP1B Assay Kit, Colorimetric
(539736, Merck Millipore, Burlington, MA, USA), following
the manufacturer’s protocol.
2.6. Statistical Analysis. The results are presented as mean ±
S:E:M. Analysis of normally distributed data was performed
using the Kolmogorov-Smirnov test. Nonnormally distrib-
uted data were subjected to natural logarithm transformation
prior to statistical analysis. Differences between experimental
groups were analysed by Student’s t-test. Overall level of
statistical significance was reached at ∗p < 0:05, ∗∗p < 0:01,
and ∗∗∗p < 0:001.
3. Results and Discussion
Recessively homozygous (fa/fa) Zucker rats display obe-
sity, hyperleptinaemia, hyperinsulinaemia, hypercholester-
olaemia, and hypertriglyceridaemia [7]. Body weight and
metabolic parameters observed in plasma were not signifi-
cantly changed after AVE0991 administration for two weeks
(Table 2). On the other hand, AVE0991 administration sig-
nificantly improved glucose tolerance evaluated by IPGTT
(Figure 1).
3.1. Local RAS Components. The expression of the classical
RAS components, namely, renin, angiotensinogen (AGT),
ACE, AT1, and AT2, was not changed in the skeletal muscle
of obese Zucker rats upon AVE0991 treatment. However, the
Table 1: Continued.
Rv 5′-GTC ACG CTT GAT AGC CTC-3′
Sod3
Fw 5′-CTT GAC CTG GTT GAG AAG ATA G-3′
Rv 5′-GAT CTG TGG CTG ATC GG-3′
Table 2: Selected metabolic parameters of control obese Zucker rats and in obese Zucker rats receiving AVE0991 via osmotic minipumps for
two weeks.
Obese control AVE0091
Statistics
n = 5 n = 4
Body weight (g) 613:00 ± 3:64 621:10 ± 4:29 p = 0:877
Fasting glycaemia (mmol/l) 6:42 ± 0:10 6:15 ± 0:22 p = 0:261
Insulin (ng/ml) 10:28 ± 1:06 10:14 ± 0:32 p = 0:914
QUICKI1 0:221 ± 0:002 0:222 ± 0:001 p = 0:829
Triglycerides (mmol/l) 3:59 ± 0:69 5:16 ± 1:05 p = 0:236
Cholesterol (mmol/l) 6:01 ± 0:35 7:13 ± 0:82 p = 0:254
HDL (mmol/l) 2:39 ± 0:25 2:00 ± 0:48 p = 0:462
LDL (mmol/l) 0:95 ± 0:04 1:36 ± 0:37 p = 0:196
VLDL (mmol/l) 1:63 ± 0:32 2:35 ± 0:48 p = 0:236
LDL/HDL 0:42 ± 0:05 0:66 ± 0:14 p = 0:110
1QUICKI: quantitative insulin sensitivity check index.
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expression of AT2 tended (p = 0:052) to decrease after
AVE0991 administration (Figure 2).
Similarly, the expression of the alternative RAS compo-
nents ACE2, Mas, and neutral endopeptidase (NEP) was
unchanged in the skeletal muscle of obese Zucker rats after
AVE0991 application for two weeks (Figure 3).
The expression of APA in the skeletal muscle tended to
increase (p = 0:057) by AVE0991 administration. Corre-
spondingly, the activity of APA was significantly elevated
(p < 0:01) in the skeletal muscle of obese Zucker rats treated
with AVE0991. The plasma APA activity was not affected
by the treatment (Figure 4).
Statistical analyses revealed a significant (p < 0:05)
increase of renin receptor (ReR) expression in the skeletal
muscle of obese Zucker rats receiving AVE0991 when com-
pared to the control group. The mRNA level of promyelocy-
tic leukemia zinc finger (PLZF; Zbtb16), the repressor of ReR
transcription, was examined as well. We observed a signifi-
cant upregulation of PLZF gene expression (p < 0:05)
induced by AVE0991 treatment (Figure 5).
3.2. Markers of Oxidative Stress and Antioxidant Defence
Mechanism. Since ReR activation is involved in the regula-
tion of NADPH oxidase 2 and 4 (Nox2 and Nox4) expres-
sion, we evaluated the mRNA levels of Nox2, Nox4, and
p22phox, the α-subunit of NADPH oxidase system. The
expression of Nox2 and Nox4 was elevated significantly
(p < 0:05), while the expression of p22phox was not affected
significantly (p = 0:095) by AVE0991 administration in the
skeletal muscle of obese Zucker rats (Figure 6).
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Figure 1: Intraperitoneal glucose tolerance test (IPGTT) evaluated in control obese Zucker rats (n = 6) and in obese Zucker rats receiving
AVE0991 (n = 5) via osmotic minipumps for two weeks. AUC: area under curve. Data are presented as mean ± S:E:M: and were analysed
using Student’s t-test, ∗p < 0:05; ∗∗p < 0:01.
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Figure 2: Classical RAS pathway components in the skeletal muscle
of obese Zucker rats. Gene expression of renin, angiotensinogen
(AGT), angiotensin-converting enzyme (ACE), angiotensin II type
1 receptor (AT1), and angiotensin II type 2 receptor (AT2) in
musculus quadriceps of control obese Zucker rats and in obese
Zucker rats receiving AVE0991 via osmotic minipumps for two
weeks, determined by real-time PCR. Data were normalized to the
gene expression of 40S ribosomal protein S29 (Rps29) whose
expression was not altered by the treatment. Data presented as
mean ± S:E:M: were analysed by Student’s t-test.
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Figure 3: Alternative RAS pathway components in the skeletal muscle
of obese Zucker rats. Gene expression of angiotensin-converting
enzyme2 (ACE2), Mas receptor, and neutral endopeptidase (NEP)
in musculus quadriceps of control obese Zucker rats and in obese
Zucker rats receiving AVE0991 via osmotic minipumps for two
weeks, determined by real-time PCR. Data were normalized to the
gene expression of 40S ribosomal protein S29 (Rps29) whose
expression was not altered by the treatment. Data presented as
mean ± S:E:M: were analysed by Student’s t-test.
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The expression of enzymes with antioxidant properties
was affected by AVE0991 treatment as well. Superoxide dis-
mutase 2 (Sod2) (p < 0:05) and nuclear factor erythroid 2-
related factor 2 (Nrf2) (p < 0:01) mRNAs were significantly
enhanced in the muscle of the treated group when compared
to the control group. The expression of Sod1 and Sod3 was
not affected significantly by the treatment (Figure 7).
3.3. Insulin Signaling. Regarding the insulin signaling cas-
cade, the protein expression and phosphorylation of insulin
receptor β subunit (IR) at Tyr1150/1151 were both signifi-
cantly (p < 0:05 and p < 0:001) upregulated in the skeletal
muscle of obese Zucker rats receiving AVE0991. The protein
content of total insulin receptor substrate (IRS1) was signifi-
cantly (p < 0:05) increased in the treated group.We evaluated
the phosphorylation of IRS1 at different amino acid residues.
Upon AVE0991 administration, IRS1 phosphorylation on
Tyr896 was increased significantly (p < 0:01), while Ser612
phosphorylation was decreased (p < 0:05). The protein con-
tent of phosphorylated IRS1 on Ser307 was unchanged by
the treatment (Figure 8).
The ratio of pIRβ at Tyr1150/1151 and total protein con-
tent of IRβ, respectively, and the ratio of pIRS1 on various
amino acid residues and total protein content of IRS1 were
calculated (Table 3). The ratios of pIRβ (Tyr1150/1151)/IRβ,
pIRS1 (Tyr896)/IRS1, and pIRS1 (Ser307)/IRS1 were unaf-
fected by the treatment, while pIRS1 (Ser612)/IRS1 ratio
was significantly reduced by AVE0991 application.
The protein content of protein tyrosine phosphatase
1B (PTP1B), a negative regulator of the insulin signaling
cascade, was (p < 0:05) decreased, accompanied by reduced
PTP1B Ser50 phosphorylation (p < 0:05) in the skeletal mus-
cle of obese Zucker rats receiving AVE0991. However, the
activity of PTP1B in the skeletal muscle was unaffected by
the treatment (Figure 9).
4. Discussion
Obese Zucker rats represent a well-known model of the
prediabetic state characterized by peripheral insulin resis-
tance, which is caused by an impaired insulin-stimulated
glucose uptake in skeletal muscle [8]. Moreover, these rats
display dyslipidemia, hyperinsulinemia [9], and a reduced
microvessel density in the musculature [10]. Several lines
of evidence show that the alternative ACE2/Ang 1-7/Mas
pathway has positive metabolic effects in the skeletal mus-
cle [1, 2]. Since the application of the peptide Ang 1-7 is
limited by its chemical properties, the nonpeptide Mas
receptor agonist—AVE0991—represents a promising com-
pound in pharmacological augmentation of the ACE2/Ang
1-7/Mas axis [3, 4]. In our study, obese Zucker rats were
administered AVE0991 for two weeks via osmotic mini-
pumps. The metabolic parameters observed in the plasma
were unchanged after the treatment. However, the glucose
tolerance evaluated by IPGTT was significantly improved
by AVE0991.
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Figure 4: Plasma and skeletal muscle APA activity. Enzyme activity of aminopeptidase A (APA) measured in the membrane fraction isolated
from the skeletal muscle and the blood plasma control obese Zucker rats and in obese Zucker rats receiving AVE0991 via osmotic minipumps
for two weeks. Gene expression of aminopeptidase A (APA) in musculus quadriceps determined by real-time PCR. Data were normalized to
the gene expression of 40S ribosomal protein S29 (Rps29) whose expression was not altered by the treatment. Data presented as mean ± S:
E:M: were analysed by Student’s t-test, ∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001.
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Since AVE0991 acts as an activator of the alternative
RAS pathway, and it is known that local skeletal muscle
RAS is affected by obesity, we evaluated the application
of AVE0991 on the expression of the local RAS components
in the skeletal muscle of obese Zucker rats. However, we did
not find any significant alterations in the expression pattern
of the classical (AGT, ACE, AT1, and renin) and/or the
alternative RAS pathway components (ACE2, Mas, and
NEP) by the treatment. In our previous study, we examined
the effect of obesity on the expression of RAS components
in the skeletal muscle. We detected a significant obesity-
and impaired glucose tolerance-related increase of AT2
expression in the group of 8-month-old Zucker rats [5].
On the contrary, AVE0991 normalized AT2 expression in
muscle of age-matched animals (present study), indicating
that impaired AT2 expression is partially reversed by
AVE0991 administration.
The membrane-bound enzyme, aminopeptidase A (glu-
tamyl aminopeptidase), catalyses the cleavage of Ang II to
Ang III [11, 12]. The origin of the soluble form in the plasma
has not been clarified yet, since there is no evidence for active
secretion from any of the tissues. We have recently detected a
significant decrease of membrane-bound APA activity in the
skeletal muscle of Zucker rats by obesity, which negatively
correlated with the plasma APA activity [5]. Simultaneously,
the plasma cholesterol levels significantly correlated with the
plasma APA activity. These data suggest that elevated plasma
cholesterol in obesity might have a stimulatory effect on
membrane-bound APA autolysis in the skeletal muscle,
which in turn contributes to the rise of plasma APA activity
in obese individuals. After AVE0991 treatment, we detected
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Figure 5: Renin receptor in the skeletal muscle of Zucker rats. Gene
expression of the renin receptor (ReR) at the level of mRNA (a) and
protein with representative Western blots (b); mRNA expression of
the transcription factor promyelocytic leukemia zinc finger (PLZF,
Zbtb16) and furin in musculus quadriceps of control obese Zucker
rats and in obese Zucker rats receiving AVE0991 via osmotic
minipumps for two weeks. Levels of mRNA were determined by
real-time PCR. Data were normalized to the gene expression of
40S ribosomal protein S29 (Rps29) whose expression was not
altered by the treatment. The amount of renin receptor protein
was quantified by Western blot method. The signal intensities of
the proteins of interest were normalized to the sample’s total
protein content stained with Coomassie Brilliant Blue. Data are
presented as mean ± S:E:M. Results were analysed by Student’s
t-test, ∗p < 0:05.
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Figure 6: Prooxidant genes in the skeletal muscle of obese Zucker
rats. Gene expression of NADPH oxidase 2 (Nox2), Nox4, and
p22phox in musculus quadriceps of control obese Zucker rats and
in obese Zucker rats receiving AVE0991 via osmotic minipumps
for two weeks, determined by real-time PCR. Data were normalized
to the gene expression of 40S ribosomal protein S29 (Rps29) whose
expression was not altered by the treatment. Data presented as
mean ± S:E:M: were analysed by Student’s t-test, ∗p < 0:05; ∗∗p <
0:01.
0
5
10
15
20
25
30
35
40
45
Sod1 Sod2 Sod3 Nrf2
p = 0.077
m
RN
A
 S
od
1,
 S
od
2,
 S
od
3,
 N
rf2
/R
ps
29
(r
el
at
iv
e u
ni
ts)
Obese
AVE0991
⁎⁎
⁎
Figure 7: Genes coding enzymes with antioxidant action in the
skeletal muscle of obese Zucker rats. Gene expression of
superoxide dismutase 1 (Sod1), Sod2, Sod3, and nuclear factor
erythroid 2-related factor 2 (Nrf2) in musculus quadriceps of
control obese Zucker rats and in obese Zucker rats receiving
AVE0991 via osmotic minipumps for two weeks, determined by
real-time PCR. Data were normalized to the gene expression of
40S ribosomal protein S29 (Rps29) whose expression was not
altered by the treatment. Data presented as mean ± S:E:M: were
analysed by Student’s t-test, ∗p < 0:05; ∗∗p < 0:01.
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Figure 8: Insulin signaling cascade in the skeletal muscle of obese Zucker rats. Protein content of total insulin receptor β subunit (IRβ),
phosphorylated IRβ at Tyr1150/1151, total insulin receptor substrate 1 (IRS1), and phosphorylated IRS1 at Tyr896, Ser307, and Ser612
with representative Western blots in musculus quadriceps of control obese Zucker rats and in obese Zucker rats receiving AVE0991 via
osmotic minipumps for two weeks. The amount of protein was quantified by Western blot method. The signal intensities of the proteins
of interest were normalized to the sample’s total protein content stained with Coomassie Brilliant Blue. Data are presented as mean ± S:E:
M. Results were analysed by Student’s t-test, ∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001.
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Figure 9: Protein tyrosine phosphatase 1B (PTP1B) in the skeletal muscle of obese Zucker rats. Protein content of total protein tyrosine
phosphatase 1B (PTP1B), phosphorylated PTP1B at Ser50 with representative Western blots, and PTP1B activity in musculus quadriceps
of control obese Zucker rats and in obese Zucker rats receiving AVE0991 via osmotic minipumps for two weeks. The amount of protein
was quantified by Western blot method, and PTP1B activity was measured using commercially available colorimetric assay kit. The signal
intensities of the proteins of interest were normalized to the sample’s total protein content stained with Coomassie Brilliant Blue. Data are
presented as mean ± S:E:M. Results were analysed by Student’s t-test, ∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001.
Table 3: Insulin signaling cascade in the skeletal muscle of control obese Zucker rats and in obese Zucker rats receiving AVE0991 via osmotic
minipumps for two weeks.
Ratio
Obese control AVE0091
Statistics
n = 5 n = 4
pIRβ (Tyr1150/1151)/IRβ 0:29 ± 0:02 0:27 ± 0:01 p = 0:689
pIRS1 (Tyr896)/IRS1 5:23 ± 1:42 4:94 ± 2:14 p = 0:884
pIRS1 (Ser307)/IRS1 66:69 ± 10:94 36:57 ± 13:62 p = 0:151
pIRS1 (Ser612)/IRS1 50:02 ± 9:93 21:39 ± 2:57 p < 0:05
Insulin receptor β subunit (IRβ), phosphorylated IRβ at Tyr1150/1151, total insulin receptor substrate 1 (IRS1), and phosphorylated IRS1 at Tyr896, Ser307
and Ser612 residues.
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a significant increase of membrane-bound APA activity
accompanied by an increasing tendency of APA expression
in the skeletal muscle, which opposes the obesity-induced
decrease of muscle APA activity described earlier [5]. It
implies that AVE0991 has the potential to normalise skeletal
muscle membrane-bound APA activity and expression in
obese Zucker rats.
Recent studies suggest the existence of a novel pathway,
where renin can act in a hormone-like fashion via the renin
receptor. The catalytic activity of renin is increased 4- to 5-
fold when bound to its receptor. Moreover, prorenin which
was considered an inactive precursor of renin gains enzy-
matic activity without proteolytical cleavage of the proseg-
ment after binding to the ReR [13]. It is known that ReR
mediates the production of ROS by both Ang II-dependent
and Ang II-independent pathways and regulates the expres-
sion of the Nox family members [14, 15]. Here, we show
for the first time that AVE0991 treatment elevates expression
of ReR in the skeletal muscle. Furthermore, the expression of
Nox2 and Nox4 is elevated as well by AVE0991 application;
however, this elevation might occur via other mechanisms,
which have not been elucidated yet.
To the best of our knowledge, this is the first study show-
ing the divergent action of AVE0991. On the one hand, it ele-
vates the expression of prooxidative genes (Nox2, Nox4),
while on the other hand, the expression of genes with antiox-
idative properties (Sods, Nrf2) is elevated upon AVE0991
treatment, establishing a new pro- and antioxidant equilib-
rium on a higher level. Several lines of evidence support a
pivotal role of endogenous ROS in the insulin signaling cas-
cade and subsequent glucose uptake by the skeletal muscle
[16–19]. Moreover, the application of antioxidants has a neg-
ative effect on skeletal muscle glucose utilisation after exer-
cise [17]. It has been proven that Nox4 inactivation results
in inhibition of insulin signaling cascade, which means that
for proper signal transduction, a certain amount of ROS is
needed [20]. Insulin after binding to its receptor triggers
rapid generation of ROS via activation of Nox4 in insulin-
responsive tissues, which facilitates signal transduction
through the insulin action pathway [20–22]. This mechanism
is mediated by the oxidative inhibition of protein tyrosine
phosphatase 1B (PTP1B) by ROS. The molecule of PTP1B
has a catalytic activity if its thiol moiety is in a reduced form,
when it acts inhibitory onto insulin signal transduction. The
IRβ subunit domain must be autophosphorylated to achieve
full receptor kinase activation, which is a target of several
protein phosphatase regulators of insulin signaling, including
PTP1B [23]. By these means, the upregulated expression of
ReR and Nox4 might contribute to oxidative inhibition of
PTP1B and subsequent facilitation of insulin signal transduc-
tion. In order to confirm this hypothesis, we evaluated the
insulin signal transduction and PTP1B protein expression
and activity in the skeletal muscle of obese Zucker rats after
AVE0991 treatment. We found a significant decrease of
PTP1B protein content as well as decreased PTP1B Ser50
phosphorylation. However, these changes were not reflected
in protein PTP1B activity measured by colorimetric assay.
It should be noted that in vitro conditions are comprising
optimal amount of the phosphopeptide substrate in the reac-
tion, which might not be the case in in vivo conditions.
Despite unchanged PTP1B activity detected, we found bene-
ficial changes in the insulin signaling cascade. Total IRβ pro-
tein content was increased in treated animals. In addition to
increased tyrosine phosphorylation of the IRβ subunit, the
experimental group displayed a significant increase in both
total IRS1 and pIRS1 Tyr896. Since both the total protein
and the phosphorylated forms were elevated, the ratios of
pIRβ/IRβ and pIRS1/IRS1 at tyrosine amino acid residues
were unaffected. On the other hand, the protein content of
phosphorylated IRS1 at Ser612 and the ratio of pIRS1
(Ser612)/IRS1 were significantly decreased. These positive
changes show that AVE0991 treatment has a beneficial effect
on the insulin signaling cascade in the skeletal muscle, which
is also reflected by the improvement of glucose tolerance in
treated animals. Our results indicate that the improvement
of insulin signaling cascade occurred via inhibition of IRS1
serine phosphorylation rather than by increased tyrosine
kinase activity in the skeletal muscle.
5. Conclusions
In summary, our results show for the first time that the non-
peptide Mas agonist—AVE0991—improved the obesity-
induced metabolic alterations in the skeletal muscle, which
was reflected by improvement of the whole-body glucose tol-
erance accompanied by elevated IRβ and IRS total protein
content and tyrosine phosphorylation and decreased serine
phosphorylation. The positive effects of AVE0991 on skeletal
muscle glucose utilisation might be—at least partially—ex-
plained by the activation of genes involved in ROS generation
and inhibition of PTP1B protein content. This mechanism is
accompanied by activation of antioxidant mechanisms, and
therefore, a new prooxidant/antioxidant balance is estab-
lished on a higher level. These findings open a new possibility
for the treatment of obesity-induced metabolic alterations in
the skeletal muscle based on mimicking the endogenous
effects of Ang 1-7.
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